Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Luxembourg

Research and Innovation Action · Running

OPT-MVAC Optimizing the delivery and uptake of malaria vaccines in countries with areas of highly seasonal transmission in West and Central Africa

Coordinator
Luxembourg Institute of Health, Luxembourg
Runs
1 January 2025 to 30 June 2029
Status
Running
EU funding
€5.3m
Total cost
€5.3m
Partners
8 organisations in 6 countries
Type
Research and Innovation Action
Grant agreement
101160139

What the project is doing

In the project's own words, from its summary on CORDIS.

The availability of effective malaria vaccines is a historic landmark, “a breakthrough for science, child health and malaria control” that “could save tens of thousands of young lives each year” [WHO 2021]. But substantial implementation challenges need to be addressed to realise this potential. In many areas where malaria vaccines will soon be introduced, EPI coverage is suboptimal, especially in the second year of life.

Introduction of malaria vaccines is also an opportunity to strengthen delivery of basic vaccines because a) additional immunisation visits will be required to administer 3 doses of malaria vaccine between the ages of 5 and 9 months and a fourth dose at about 2 years, and b) in areas with highly seasonal malaria, annual intensification of vaccine delivery may be advantageous to optimize malaria impact, both providing opportunities for catch-up of other vaccines, and c) recognition of the importance of malaria may lead to be less mistrust of malaria vaccines, as observed during pilot implementations; such positive attitudes could be leveraged to promote vaccination in general.

The purpose of this project is to support national immunization and malaria programmes in 14 countries in West and Central Africa with highly seasonal malaria, to optimize delivery and uptake of malaria vaccines, and to exploit the opportunities to strengthen delivery of other vaccines. This will be achieved through a programme of implementation research, adapting delivery approaches to local situations, and sharing information about what works best.

The project, which builds on a network of 13 countries that was established through the EDCTP-funded OPT-SMC project, coordinated by the University of Thiès in Senegal, the LIH, TDR, LSHTM, CAPM, MMV and WHO, will provide technical assistance to national programmes to enable them to monitor vaccine introduction and identify barriers to uptake, and develop, implement, and evaluate strategies to address these barriers.

Who is involved

OrganisationCityCountryRole
Luxembourg Institute of HealthStrassenLuxembourgCoordinator
Mmv Medicines for Malaria VentureCointrinSwitzerlandAssociatedpartner
World Health OrganizationGeneveSwitzerlandParticipant
European Vaccine Initiative eVHeidelbergGermanyParticipant
Rabat Collaborating Center for strengthening pharmacovigilanceKenitraMoroccoAssociatedpartner
Universite Cheikh Anta Diop De DakarDakar FannSNThird party
Universite Iba Der Thiam De ThiesThiesSNParticipant
London School of Hygiene and Tropical Medicine Royal CharterLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI